Hikal Posts Net Loss Amid Auditor Concerns and USFDA Warning

CHEMICALS
Whalesbook Logo
AuthorAkshat Lakshkar|Published at:
Hikal Posts Net Loss Amid Auditor Concerns and USFDA Warning
Overview

Hikal Ltd. reported a consolidated net loss of ₹59 million for Q3 FY26, a sharp reversal from a profit in the prior year, despite a 10.4% rise in revenue to ₹4,943 million. The loss was driven by an exceptional item of ₹380 million. Compounding concerns are a modified auditor's review report citing revenue recognition irregularities and environmental compliance issues, alongside a USFDA warning letter impacting its pharmaceutical segment sales.

📉 The Financial Deep Dive

The Numbers: Hikal Ltd. announced its Q3 FY26 results, revealing a consolidated net loss of ₹59 million, a stark contrast to the ₹172 million profit recorded in Q3 FY25. This resulted in basic Earnings Per Share (EPS) turning negative at ₹(0.48) from ₹1.39 year-on-year. Despite the bottom-line contraction, revenue from operations demonstrated resilience, growing by 10.4% to ₹4,943 million in Q3 FY26 from ₹4,477 million in the same period last year. However, the reported net loss was significantly influenced by an exceptional item of ₹380 million recognized in Q3 FY26, attributed to the adoption of new labor codes and changes in gratuity policy. For the nine months ended December 31, 2025, the consolidated net loss widened to ₹632 million from a profit of ₹406 million in 9MFY25, with revenue declining by 8.7% to ₹11,932 million.

Segment Performance: The Pharmaceuticals segment showed strength, with revenue climbing 15.0% YoY to ₹3,373 million and segment results improving by 24.2% to ₹415 million. In contrast, the Crop Protection segment saw only marginal revenue growth of 1.7% to ₹1,570 million, but its segment results plummeted by 65.5% to ₹48 million from ₹139 million in Q3 FY25.

The Grill: A significant point of concern is the modified review conclusion from the statutory auditors in both standalone and consolidated reports. The auditors flagged pending outcomes of the company's fact-finding review into irregularities in revenue recognition timing and uncertainty regarding investigations into alleged non-compliance with environmental laws. Furthermore, a USFDA warning letter issued in August 2025 for the Jigani facility has led to customers deferring purchases, directly impacting Pharma segment sales.

🚩 Risks & Outlook

The company declared an interim dividend of 10% or ₹0.20 per equity share for FY25-26. However, the modified auditor's opinion is a major red flag, indicating potential governance and accounting control weaknesses. The ongoing investigations into environmental compliance and the impact of the USFDA warning letter pose substantial risks to future revenue streams and regulatory standing. Investors will closely monitor the resolution of these issues and the performance of the Crop Protection segment, which has shown significant profitability decline.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.